DAPTOMYCIN
Generic: DAPTOMYCIN
Sagent PharmaceuticalsManufacturer
INTRAVENOUSRoute
DAPTOMYCINActive Substance
2019-11-15Original Approval
DAPTOMYCIN is FDA application ANDA207104, sponsored by SAGENT PHARMS INC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-08-06
Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1,000 mg total, in 1000 mL Single Dose CoCGMP Deviations
Class II2026-08-06
Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose ContainerCGMP Deviations
Class I2020-07-07
Daptomycin for Injection, 500 mg/vial, Single-Dose Vial, Rx only, Sterile, Manufactured for: Mylan Institutional, LLC, RPresence of Particulate Matter
Class II2023-02-07
Daptomycin for Injection 500 mg per vial, Single-dose vial, Rx only, Manufactured by: Intas Pharmaceuticals Limited, PhaCGMP Deviations: recalling drug products following an FDA inspection.
Class II2023-02-07
Daptomycin for Injection 350 mg/vial, Rx only, Packaged as: a) Single-dose vial NDC 16729-434-05 UPC 3 16729 43405 8; b)CGMP Deviations: recalling drug products following an FDA inspection.
Top Reported Reactions
1
DRUG INEFFECTIVE
768 reports
2
OFF LABEL USE
703 reports
3
ACUTE KIDNEY INJURY
628 reports
4
EOSINOPHILIC PNEUMONIA
489 reports
5
PYREXIA
481 reports
6
RHABDOMYOLYSIS
389 reports
7
EOSINOPHILIA
387 reports
8
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
344 reports
9
BLOOD CREATINE PHOSPHOKINASE INCREASED
329 reports
10
PRODUCT USE IN UNAPPROVED INDICATION
321 reports